Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AH1206
- Development stage
- Phase 2
- Lead developer
- Alimentary Health
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
AH1206 is a live biotherapeutic product consisting of a specific strain of the bacterium *Bifidobacterium longum*. Developed by Alimentary Health Ltd, it has been evaluated in clinical trials for the treatment of irritable bowel syndrome (IBS). The mechanism of action involves the modulation of the host's gut microbiota and the regulation of the mucosal immune system. Specifically, AH1206 is thought to promote an anti-inflammatory environment within the gastrointestinal tract by influencing cytokine production, such as increasing the levels of the anti-inflammatory cytokine interleukin-10 and potentially reducing pro-inflammatory markers like tumor necrosis factor. It was studied in a Phase 2, double-blind, randomized, placebo-controlled trial to assess its safety and efficacy in improving IBS symptoms in adult women, utilizing a 7-point Likert global improvement scale.
- Other names
- Bifidobacterium longum AH1206
Beyond the preview
Go deeper on AH1206.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AH1206.